Intravenous Administration of Recombinant Adenoviruses Causes Thrombocytopenia, Anemia and Erythroblastosis in Rabbits

Journal of Gene Medicine

Volumn 1, Issue 5, 1999, Pages 360-371

  Cichon, Günter ^a   Schmidt, Hartmut H ^b   Benhidjeb, Tahar ^c   Löser, Peter ^d   Ziemer, Sabine ^e   Haas, Regina ^b   Grewe, Nicole ^b   Schnieders, Frank ^a   Heeren, Jörg ^f   Manns, Michael P ^b   Schlag, Peter M ^c   Strauss, Michael ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b University Clinic   (Germany)

^c Section of Pathology   (Germany)

^d HepaVec AG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Adenovirus; Biodistribution; Erythroblast; Gene therapy; Rabbit; Thrombocytopenia

Indexed keywords

ADENOVIRIDAE; MAMMALIA; ORYCTOLAGUS CUNICULUS;

ADENOVIRUS; ANEMIA; ANIMAL; ARTICLE; ERYTHROBLAST; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; LACTOSE OPERON; METHODOLOGY; MOUSE; PATHOGENICITY; PATHOLOGY; PORTAL VEIN; RABBIT; THROMBOCYTOPENIA; TIME; TISSUE DISTRIBUTION;

ADENOVIRIDAE; ANEMIA; ANIMALS; ERYTHROBLASTS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; LAC OPERON; MICE; PORTAL VEIN; RABBITS; RECOMBINATION, GENETIC; THROMBOCYTOPENIA; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0033181742     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-2254(199909/10)1:5<360::AID-JGM54>3.0.CO;2-Q     Document Type: Article

References (43)

1. Goldman MJ, Litzky LA, Engelhardt JF, Wilson JM. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther 1995; 6: 839-851.
2. Korst RJ, McElvaney NG, Chu CS, et al. Gene therapy for the respiratory manifestations of cystic fibrosis. Am JRespir Crit Care Med 1995; 151: S75-S87.
3. McDonald RJ, Lukason MJ, Raabe OG, et al. Safety of airway gene transfer with Ad2/CFTR2: aerosol administration in the nonhuman primate. Hum Gene Ther 1997; 8: 411-422.
4. Petrof BJ. Respiratory muscles as a target for adenovirus-mediated gene therapy. Eur Respir J 1998; 11: 492-497.
5. Yang L, Lochmuller H, Luo J, et al. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene. Ther 1998; 5: 369-379.
6. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett 1998; 425: 329-336.
7. Smith TA, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996; 3: 496-502.
8. Smith TA, Mehaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
9. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
10. Barr D, Tubb J, Fergusōn D, et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther 1995; 2: 151-155.
11. Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997; 8: 1275-1286.
12. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-810.
13. Li J, Fang BL, Eisensmith RC, et al. In vivo gene therapy for hyperlipidemia: Phenotypic correction in watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995; 95: 768-773.
14. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702.
15. Armentano D, Zabner J, Sacks C, et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408-2416.
16. Lochmuller H, Petrof BJ, Pari G, et al. Transient immunosuppression by Fk506 permits a sustained high level dystrophin expression after adenovirus mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther 1996; 3: 706-716.
17. Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997; 99: 1098-1106.
18. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A 1993; 90: 2812-2816.
19. Weibel R, Stäubli W, Gnägi MR. Correlated morphometric and biochemical studies on the liver cell - 1. Morphometric model and normal moprhometric data for rat liver. J Cell Biol 1969; 42: 68-91.
20. Gates GA. The human liver. J Lab Clin Med 1961; 57(2): 182-184.
21. Wanson JC, Bernaert D, May C. Morphology and functional properties of isolated and cultured hepatocytes. In Progress in Liver Diseases, Popper F (ed), New York: Schaffner, Grune & Sratton Inc, 1979; 6: 1-22.
22. Nyberg Hoffman C, Shabram P, Li W, Giroux D, Aguilar Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
23. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
24. Baranski B, Young N. Hematologic consequences of viral infections. Hematol Oncol Clin North Am 1987; 1: 167-183.
25. Zucker Franklin D. The effect of viral infections on platelets and megakaryocytes. Semin Hematol 1994; 31: 329-337.
26. Abzug MJ, Levin MJ. Neonatal adenovirus infection: four patients and review of the literature. Pediatrics 1991; 87: 890-896.
27. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107-115.
28. Kass Eisler A, Falck Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1994; 1: 395-402.
29. Vrancken Peeters MJ, Perkins AL, Kay MA. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 1996; 20: 278-285.
30. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
31. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997; 94: 3352-3356.
32. Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. J Virol 1994; 68: 6811-6814.
33. Torres JM, Alonso C, Ortega A, Mittal S, Graham F, Enjuanes L. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J Virol 1996; 70: 3770-3780.
34. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
35. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
36. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565-13570.
37. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988; 163: 614-617.
38. Channon KM, Qian HS, Youngblood SA, et al. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function [see comments]. Circ Res 1998; 82: 1253-1262.
39. Sakamoto H, Ochiya T, Sato Y, et al. Adenovirus-mediated transfer of the HST-1 (FGF4) gene induces increased levels of platelet count in vivo. Proc Natl Acad Sci U S A 1994; 91: 12368-12372.
40. Konishi H, Ochiya T, Sakamoto H, et al. Effective prevention of thrombocytopenia in mice using adenovirus-mediated transfer of HST-1 (FGF-4) gene [published erratum appears in J Clin Invest 1995 Nov; 96(5): 2543]. J Clin Invest 1995; 96: 1125-1130.
41. Ohwada A, Rafii S, Moore MA, Crystal RG. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Blood 1996; 88: 778-784.
42. Sullivan DE, Dash S, Du H, et al. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997; 8: 1195-1206.
43. Raper SE, Haskal ZJ, Ye X, Pugh C, Furth EE, Gao GP, Wilson JM. Selective gene trasfer into the liver of non-human primates with El-deleted, E2A-defective or E1-E4 deleted recombinant adenoviruses. Hum Gene Ther 1998; 9(5): 671-679.